ODYY · Odyssey Health, Inc.

This cancellation represents a material strategic reversal for Odyssey Health, terminating its planned commercial role for BreastCheck — a product central to recent public disclosures and investor expectations. The agreement’s collapse stems directly from NeuRX’s failure to secure Davion’s mandatory consent, a condition NeuRX had expressly warranted was satisfied in its agreement with Odyssey. Davion’s explicit refusal to retroactively approve the sublicense — and its directive that Odyssey publicly retract prior announcements — introduces reputational and regulatory risk, particularly given Odyssey’s status as a publicly traded company. The revocation eliminates Odyssey’s anticipated revenue stream and operational involvement in BreastCheck distribution and manufacturing, with no disclosed transition provisions, termination payments, or alternative arrangements. Because the agreement had already closed and was presumably integrated into Odyssey’s near-term business planning, this event materially disrupts execution capability and may trigger reassessment of management’s diligence in third-party licensing due diligence. Investors should note the absence of any mitigation language, indemnification terms, or dispute resolution mechanisms referenced in the filing, leaving Odyssey without apparent recourse against NeuRX for reliance damages.